The antitumor efficacy of compound (136) was validated in xenograft models, where it effectively inhibited the PI3K pathway by reducing levels of p-AKT, p-S6, and p-4EBP1 in tumor tissues. This evidence concerns the gene PIK3CD and neoplasm.